Dr. Toru Miyazaki (宮崎徹博士) of the AIM Medical Research Institute, who has been leading the development of a feline kidney disease treatment based on the AIM protein, announced in June the launch of a nationwide clinical trial of the new AIM-based medication for cats.
The trial will be conducted simultaneously at 26 veterinary hospitals across Japan and is based on data collected through pre-screening blood tests from a large number of cat guardians.
Dr. Miyazaki shared the background and his personal thoughts on the start of the trial via his social media, stating:
“Thanks to the cooperation of so many people, we were able to obtain valuable information through the blood sampling process, and now, the clinical trial of the AIM-based feline medication has finally begun.
I sincerely apologize that, due to the nature of the trial, not all cats can participate.
We will do our utmost to secure approval as soon as possible. Thank you for your continued support.”
This clinical trial marks a critical step toward official approval of the new medication, and the ongoing interest and support of cat guardians will be more important than ever.
Greycoat Research has already been supporting cat guardians around the world through the Dr. Toru Protocol, a supplement based on Dr. Miyazaki’s research, and will continue to share updates on the latest developments in feline kidney disease treatment.
